December 5-7th, 2017

Miami, FL

REGISTER HERE

Day One
Tuesday December 5th, 2017

Day Two
Wednesday December 6th, 2017

08.00
Registration & Coffee

09.00
Chair’s Opening Remarks

Improving Delivery of OVs Intravenous vs. Intratumoral

09.30
Local LOAd703 Virus Administration Results in Enhanced Efficacy Compared to Systemic Treatment.

Synopsis

  • In this project, systemic versus local (intratumoral) administration have been compared in vivo with or without neutralizing antibodies (nAbs) to understand if also local delivery is
    hampered by nAbs
  • The treatment effect was better using local delivery likely due to the higher concentration of virus reaching the tumor
  • Further, nAbs abolished the effect of systemic LOAd703 while local delivery could still control the tumor. Local delivery was effective in a wide range of tumor models and could be combined with systemic chemotherapy or checkpoint blockade antibodies
  • Local (intratumoral) delivery is effective despite the presence of neutralizing antibodies
  • Systemic (intravenous) delivery is hampered by neutralizing antibodies
  • LOAd703 is potent across different tumor models and can be combined with chemotherapy or checkpoint blockade antibodies

10.00
Achieving the Right Viral Volumes and Dosages Effectively

Synopsis

  • Increasing yields/decreasing costs for large scale manufacture of oncolytic virotherapies
  • Producing viruses at large doses whilst driving down cost of goods
  • Outsourcing GMP virus manufacture and ensuring reliable products
  • How do we ensure this is a commercially viable product that can be administered globally?

10.30
Morning Refreshments & Networking

11.00
PANEL: How Can We Improve The Efficacy of Oncolytic Virotherapies?

Synopsis

  • Viral modulation of the tumor microenvironment
  • Increasing the viral impact with activated immune responses
  • Combination drug therapies to stimulate the immune response and prevent immunosuppression
  • Viral delivery for largest impact

Clinical Trial Case Studies

Synopsis

Hear updates on the most advanced clinical programs to discover how the application of oncolytic virues is being successfully utilised in the clinic.

12.00
Vaccinia Virus-based Oncolytic Immunotherapy: Ongoing Early and Late Stage Clinical Development

Synopsis

  • IPexa-Vec (pexastimogene devacirepvec, JX-594) is an oncolytic and immunotherapeutic vaccinia virus (Wyeth strain) which selectively replicates in and destroys cancer cells.
  • A randomized open-label Ph 3 study conducted by Transgene’s partner SillaJen is ongoing comparing the efficacy and tolerability of Pexa-Vec plus sorafenib vs sorafenib in advanced first line HCC patients
  • An update of Transgene’s early stage clinical trials in various indications and in combination with checkpoint blockade will be presented
  • Furthermore, operational hurdles encountered in the set-up of clinical trials and educational measures developed for physicians and clinical staff will be discussed
  • TG6002 is an oncolytic vaccinia virus (Copenhagen strain) armed with Fcu1, a chimeric enzyme which locally activates the prodrug 5-FC into 5-Fu at the tumor replication site
  • Preclinical studies have shown a strong contribution of the immune system in the mechanism of action
  • The clinical development of TG6002 is currently starting, with a planned Ph1/2a trial in glioblastomaby the intravenous (IV) route, and possibly gastrointestinal tumors

12.30
Oncolytic Herpes Virus Therapy for Mesothelioma: A Phase 1/2a Trial of Intrapleural Administration of Seprehvir

  • Joe Conner VP, Oncolytic Immunotherapy, Virttu Biologics, A Sorrento Company

13.00
Lunch & Networking

14.00
VSV-IFNb-NIS and MV-NIS: A Tale of Two Paradigms.

Synopsis

Vyriad is committed to a multiplatform approach to oncolytic immunovirotherapy. The company is currently evaluating VSV and measles oncolytic platforms in early stage clinical trials, and has additional platforms in preclinical development.

  • VSV-IFNb-NIS is a low seroprevalence oncolytic virus that drives high level intratumoral IFNb to harness multiple tumor killing mechanisms.
  • MV-NIS is a fusogenic measles virus which can persist even in measles-immune subjects, providing a durable stimulus to antitumor immunity.
  • The NIS transgene is used for pharmacokinetic imaging of virus spread and to boost efficacy with targeted radioiodine therapy
  • Both MV-NIS and VSV-IFNb-NIS have been shown to impact antitumor immunity and induce tumor regression
  • Each virus has unique advantages and single agent clinical trials are currently being pursued with combination trials envisaged.

14.30
Immune and Genetic Markers in Randomized Clinical Studies using REOLYSIN®

Synopsis

  • Clinical research to date in the field of oncolytic virus immunotherapy has yielded promising results. However, as with any novel therapeutic area, it has also presented many challenges
  • In order to effectively treat patients, much remains to be discovered regarding the genetic profiles and other characteristics of patients who are most likely to benefit from this type of therapy which are likely specific to each viral vector employed, and the optimal treatment protocols to ensure maximum patient benefit
  • Such questions can only be answered definitively in a randomized clinical trial setting
  • This presentation will examine the lessons thus far from Oncolytics’ randomized studies in head and neck, ovarian, pancreatic, prostate, squamous cell NSCLC, adenocarcinoma of the lung, and colorectal cancer utilizing its oncolytic virus, REOLYSIN®, in an immunotherapeutic context, and explore outstanding areas of enquiry in the field

14.45
Toca-511: A Translational Case Study from Bench to Bedside

15.00
Retroviral Replicating Vectors: A Versatile Platform Technology for Immuno-Gene-Virotherapy

  • Noriyuki Kasahara Professor, Departments of Cell Biology and Pathology, University of Miami

15.30
Ensuring Long Term Durable Responses and Corresponding Survival

  • Douglas Jolly EVP, Research & Pharmaceutical Development , Tocagen

16.00
Chair’s Closing Remarks: The Future of Oncolytic Virotherapies

16.15
Close of Summit